Advertisement
Breastfeeding is associated with a reduced risk of childhood leukemia compared to the risk for children who were never breastfed

Breastfeeding Tied to Lower Odds of Childhood Leukemia

0
One more potential benefit for breastfed babies, research suggests
Mortality rates among five-year childhood cancer survivors 15 years after diagnosis have been halved since the 1970s -- falling from 12.4 to 6 percent

ASCO: Longevity Improving for Childhood Cancer Survivors

0
Fewer die of 'late effects' from radiation, chemotherapy
The drug elotuzumab reduces the risk of cancer progression and mortality by 30 percent when combined with the standard two-drug therapy for multiple myeloma

ASCO: Elotuzumab Shows Benefit in Multiple Myeloma

0
Survival gains when elotuzumab was added to treatment
Targeted radiation in the treatment of brain metastases leads to less cognitive damage than radiation for the entire brain

ASCO: Risks of Whole Brain Radiotx May Outweigh Benefits

0
Second study suggests new immunotherapy may benefit patients with glioblastoma

May 2015 Briefing – Hematology & Oncology

0
Here are what the editors at HealthDay consider to be the most important developments in Hematology & Oncology for May 2015. This roundup includes...
Thousands of breast cancer patients in the United States might be spared a second surgery if more tissue was removed during initial breast-conserving

ASCO: Greater Breast Tissue Removal Reduces Further Surgery

0
Removing extra tissue can halve the chances of requiring a second surgery in breast cancer
Adding palbociclib (Ibrance) to standard hormone therapy may benefit patients with advanced hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer over hormone therapy alone

ASCO: Palbociclib Ups Survival in HR+ Metastatic Breast Cancer

0
Adding palbociclib to standard hormone therapy kept disease from progressing for nine months
Not all melanoma patients need surgery to remove lymph nodes surrounding their tumor

ASCO: Lymph Node Sx Doesn’t Benefit All Melanoma Patients

0
Second study supports new immunotherapy for enhanced survival in advanced melanoma
Two new targeted treatments have shown promise in slowing the progression of recurring chronic-lymphocytic leukemia and slow-growing non-Hodgkin's lymphoma

ASCO: Rx Strategies Promising for CLL, Non-Hodgkin’s Lymphoma

0
Ibrutinib, obinutuzumab slow progression of CLL, non-Hodgkin's lymphoma
The first genetic marker to predict response to pembrolizumab (Keytruda) has been identified by researchers

ASCO: MMR Deficiency Predicts Pembrolizumab Response

0
Findings may help doctors better choose patients to receive pembrolizumab (Keytruda)